Georgia is currently home to 1909 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
NCT04469530
Recruiting
The primary objective of this study is to improve the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus administered on a backbone of metronomic chemotherapy following the completion of "standard" therapy, as compared to high-risk solid tumor patients treated with observation alone following completion of "standard" therapy.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
11/11/2024
Locations: Aflac Cancer & Blood Disorders Centers, Atlanta, Georgia
Conditions: Solid Tumor
Register for Updates
D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)
NCT04411199
Recruiting
Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to Assess Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SoC), Compared to a SoC Treated Control Arm, in Prevention of Post Abdominal Surgery Incisional Infection.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/11/2024
Locations: Augusta Univeristy, Augusta, Georgia
Conditions: Surgical Site Infection, Colon Surgery, Abdominal Surgery, Post-Op Infection
Register for Updates
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
NCT02616302
Recruiting
Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube that carries food and liquids from the mouth to the stomach. The body uses stomach acid to break down food, but when acid rises up into the esophagus it can hurt or damage it. People with GERD often feel food coming back up into the throat and mouth and have a burning feeling in their stomach, chest, or throat, called heartburn. Other symptoms of... Read More
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
11/11/2024
Locations: Children's Center for Digestive Health Care, LLC, Atlanta, Georgia
Conditions: Gastroesophageal Reflux Disease (GERD)
Register for Updates
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06128044
Recruiting
CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the study treatment) in adults with acute myeloid leukemia (AML) that has come back after prior treatment (relapsed) or did not respond or is no longer responding to other treatment (refractory). Participants must have received at least 1 but not more than 3 prior lines of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: The Blood & Marrow Transplant Group of Georgia (BMTGA), Atlanta, Georgia
Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Register for Updates
Smart Checklist Implementation for Pediatric Tracheal Intubations in the ICU- Multicenter Study
NCT06085326
Recruiting
The purpose of the study is to implement a patient-provider dyad tailored, Electronic Health Record (EHR)-informed, digitized Smart Checklist as a Quality Improvement (QI) intervention to support bedside clinician teams to reduce Adverse Airway Outcomes (AAO) across 6 diverse pediatric intensive care units (ICUs).
Gender:
ALL
Ages:
19 years and below
Trial Updated:
11/08/2024
Locations: Emory University, Atlanta, Georgia
Conditions: Intubation Complication
Register for Updates
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
NCT05667493
Recruiting
The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: Piedmont Heart of Fayetteville, Atlanta, Georgia
Conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Register for Updates
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): the CORCINCH-HF Study
NCT04331769
Recruiting
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: Emory University, Atlanta, Georgia
Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
Register for Updates
Effectiveness of Empowerment Group Sessions for Treating Suicidal African American Women in Abusive Relationships
NCT00601939
Recruiting
This study will evaluate the effectiveness of culturally competent psychoeducational empowerment sessions in treating suicidal African-American women who are in abusive relationships.
Gender:
FEMALE
Ages:
Between 18 years and 64 years
Trial Updated:
11/08/2024
Locations: Grady Hospital, Atlanta, Georgia
Conditions: Battered Women, Suicide, Attempted
Register for Updates
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
NCT05287126
Recruiting
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to \< 18 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment), or until marketing authorization is obtained in the participant's country, which... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
11/07/2024
Locations: Children's Center for Digestive Health Care, LLC, Atlanta, Georgia
Conditions: Ulcerative Colitis
Register for Updates
Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients With Brain Tumors
NCT04908709
Recruiting
This trial studies how well spectroscopic magnetic resonance imaging (MRI) guided proton therapy works in assessing metabolic change in pediatric patients with brain tumors. The non-invasive imaging, such as spectroscopic MRI may help to map the differences in tumor metabolism compared to healthy tissue without injection of any contrast agent.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
11/07/2024
Locations: Emory Proton Therapy Center, Atlanta, Georgia
Conditions: Malignant Brain Glioma
Register for Updates
The Precision CAD Trial
NCT04755413
Recruiting
People with Coronary Artery Disease (CAD) have narrow or blocked arteries that supply blood to the heart. Reduced blood flow to the heart muscle from CAD can cause chest pain or aching, especially with exercise or activity. CAD can lead to weakening of the heart muscle or heart failure, and a higher risk of heart attack or death. Certain proteins in the blood, known as biomarkers, can be found in people with CAD. Higher levels of these biomarkers are associated with a greater risk of complicatio... Read More
Gender:
ALL
Ages:
Between 21 years and 90 years
Trial Updated:
11/07/2024
Locations: Emory Johns Creek Hospiatl, Atlanta, Georgia
Conditions: Coronary Artery Disease
Register for Updates
Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)
NCT04315324
Recruiting
This phase II trial studies how well OBI-3424 works in treating patients with T-cell acute lymphoblastic leukemia that has come back (relapsed) or does not response to treatment (refractory). Drugs used in chemotherapy, such as OBI-3424, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. OBI-3424 may reduce the amount of leukemia in the body.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia
Register for Updates